drugset

drugset / Trial / NCT00388349

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

NCT00388349 ↗

Phase 2 Completed 146 enrolled Stanford University National Institute of Allergy and Infectious Diseases (NIAID) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease

Timeline

Start: 2001-09
Primary completion: 2008-03
Completion: 2010-09

Publications

Background Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010 Aug;16(8):1145-54. doi: 10.1016/j.bbmt.2010.02.022. Epub 2010 Mar 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Etoposide	Small molecule	—	—
Background	Vinorelbine	Small molecule	—	—
Background	carmustine	Small molecule	—	—

Indications